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Abstract
Caudwell Xtreme Everest (CXE) is a large healthy volunteer field
study investigating human adaptation to environmental hypoxia.
More than 200 individuals were studied at sea-level and in four
laboratories on the trek to Everest Base Camp (5,300 m). Fifteen
physicians climbed high on Everest and continued the studies as
they ascended; eight of these individuals reached the summit of
Everest and succeeded in sampling arterial blood at 8,400 m on
their descent. Core measurements included cardiopulmonary
exercise testing, neuropsychological assessment, near infra-red
spectroscopy of brain and exercising muscle, blood markers and
daily recording of simple physiological variables. The goal of CXE
is to further our understanding of human adaptation to cellular
hypoxia, a fundamental mechanism of injury in critical illness, with
the aim of improving the care of critically ill patients.
Caudwell Xtreme Everest (CXE) is a large, healthy volunteer
field study investigating human adaptation to environmental
hypoxia [1]. The project is organised by the Centre for
Altitude Space and Extreme Environment Medicine (CASE
Medicine) at University College London. During April and May
2007 more than 200 individuals were studied as they were
progressively exposed to hypobaric hypoxia on the trek to
Everest Base Camp at 5,300 m. Most of these individuals
were volunteers who gave up their holidays to be participants
in the study. The remainder was comprised of doctors and
scientists, 15 of whom continued the studies as they
ascended up to 8,000 m. Eight of these investigators
reached the summit of Everest and on their descent took the
first measurement of arterial oxygen levels above 8,000 m. So
what is the relevance of CXE to intensive care medicine?
Cellular hypoxia is a fundamental mechanism of injury in the
critically ill [2,3]. Indeed, it is hard to think of a critically ill
patient in whom cellular hypoxia, either local or generalized, is
not present. Hypoxia may occur as either a cause of or as a
consequence of a variety of critical illnesses. Hypoxia
mediated cell death may lead to the generation of an
inflammatory response. Systemic inflammation is associated
with the development of cellular hypoxia caused by decreased
tissue oxygen delivery associated with microcirculatory
dysfunction. Cellular hypoxia may also be caused by
alterations in cellular energy pathways and mitochondrial
function, resulting in decreased ability to utilize available
oxygen [2,3]. Although our dominant treatment paradigm
revolves around maintenance of oxygen delivery to the cells,
there are few data to guide the optimal level of inspired
oxygen. Moreover, in some circumstances increasing oxygen
delivery confers no benefit or may even cause harm; for
example, elevating haemoglobin levels or 'optimization' of
oxygen delivery to specific goals in established critical illness
[4-6]. Might it be that variations in the cellular efficiency of
oxygen metabolism account for some of the observed
differences in outcome following critical illness?
The high altitude physiology literature gives us an elegant
general description of adaptation to environmental hypoxia
built around the idea that maintenance of oxygen delivery to
the tissues will allow normal cellular function [7]. However, to
date none of these adaptations explain observed (and
dramatic) differences in performance between individuals at
altitude. Again, the possibility that observed differences are
not accounted for by variations in elements of the dominant
paradigm raises the possibility that an unmeasured factor or
factors may be important. The core hypothesis that CXE is
addressing is that variations in metabolic efficiency
(relationship between oxygen uptake and work rate) may
explain, at least in part, observed differences in individuals'
abilities to adapt to hypoxia. If this is true, then it may be
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possible - by examining the genotype and phenotype of the
'rapid adaptors' - to identify mechanisms and thereby develop
treatments to benefit the 'slow adaptors' [8-10]. 
The studies conducted in CXE involve a variety of techniques,
including cardiopulmonary exercise testing on cycle ergo-
meters using breath-by-breath expired gas analysis, neuro-
psychological assessment, near infrared spectroscopy of
brain and exercising muscle, blood markers (inflammatory and
neuroendocrine) and daily recording of simple physiological
variables [1]. These measurements and many more were
taken in London before departure, in four laboratories in
Nepal on the ascent to Everest Base Camp, and in two
laboratories high on Mount Everest. The next few years will
see whether this new approach to investigating the
pathogenesis of critical illness bears fruit.
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